Added value of this study
tumours
TUMOURS, METASTATIC PROSTATE CANCER
To our knowledge, this is the first phase 1 trial to assess the activity of a single priming dose of targeted radioligand therapy coupled with immune checkpoint inhibition in patients with metastatic prostate cancer. We observed durable objective responses in a subset of patients, in whom we observed upregulation of circulating T-cell subsets and downregulation of immunosuppressive myeloid precursors, including patients with tumours with low expression of prostate-specific membrane antigen.